Cargando…
Management of clozapine treatment during the COVID-19 pandemic
Clozapine is the only available treatment for refractory schizophrenia but its use involves frequent physical contact with healthcare workers for the purpose of mandatory blood monitoring. During the COVID-19 pandemic, patients taking clozapine will be self-isolating to reduce the risk of infection,...
Autores principales: | Gee, Siobhan, Gaughran, Fiona, MacCabe, James, Shergill, Sukhi, Whiskey, Eromona, Taylor, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256815/ https://www.ncbi.nlm.nih.gov/pubmed/32542111 http://dx.doi.org/10.1177/2045125320928167 |
Ejemplares similares
-
Outcomes in treatment-resistant schizophrenia: symptoms, function and
clozapine plasma concentrations
por: Krivoy, Amir, et al.
Publicado: (2021) -
Clozapine haematological monitoring for neutropenia: a global perspective
por: Oloyede, Ebenezer, et al.
Publicado: (2022) -
Real-world effectiveness of admissions to a tertiary treatment-resistant psychosis service: 2-year mirror-image study
por: Casetta, Cecilia, et al.
Publicado: (2020) -
Distinctive pattern of neutrophil count change in clozapine-associated, life-threatening agranulocytosis
por: Taylor, David, et al.
Publicado: (2022) -
Closure beyond clozapine: successfully averting rebound symptoms in a patient with schizoaffective disorder and agranulocytosis
por: Green, Alastair, et al.
Publicado: (2019)